Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 4.97K
-1.52%-3.42%+20.92%+30.78% 245B
-0.47%-1.85%+4.16%+0.11% 154B
+0.21%+2.16%-5.79%+40.49% 146B
+1.11%-3.69%-56.16%-19.34% 60.26B
-1.80%-2.41%+9.80%+14.30% 49.44B
-0.54%-2.40%+21.37%+52.00% 47.67B
-0.78%+0.76%-21.16%-19.35% 48.04B
+0.83%-0.21%-6.98%+35.90% 45.74B
-1.57%-2.34%+34.80%+60.48% 42.84B
Average -0.51%-1.73%+0.11%+21.71% 93.2B
Weighted average by Cap. -0.94%-2.10%+3.80%+22.42%
Logo SpectraScience, Inc.
SpectraScience, Inc. is focused on developing its WavSTAT Optical Biopsy System (WavSTAT). The WavSTAT employs a risk technology that optically illuminates tissue in real-time to distinguish between normal and pre-cancerous or cancerous tissue. The Company has developed a technology platform to determine if tissue is normal, pre-cancerous or cancerous, without the need for a physical biopsy. The WavSTAT4 Optical Biopsy System operates by using cool, safe ultraviolet (UV) laser light to optically illuminate and analyze tissue, enabling the physician to make a diagnosis during endoscopy when screening for cancer and, if warranted, to begin immediate treatment during the same procedure. The WavSTAT4 uses laser-induced auto-fluorescence to obtain spectral information from tissue at the suspected site. The system is classified as a non-significant risk device, which transmits low-level UV laser light energy through an optical fiber to the tissue through the working channel of an endoscope.
Employees
7
  1. Stock Market
  2. Stocks
  3. SCIE Stock